Compare DNA & SDHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNA | SDHY |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 404.4M |
| IPO Year | 2020 | N/A |
| Metric | DNA | SDHY |
|---|---|---|
| Price | $7.84 | $15.43 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 61.6K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.46% |
| EPS Growth | ★ 46.49 | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | ★ $170,155,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.45 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.37 | $15.55 |
| 52 Week High | $17.58 | $17.10 |
| Indicator | DNA | SDHY |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 25.32 |
| Support Level | $6.38 | N/A |
| Resistance Level | $7.70 | $16.23 |
| Average True Range (ATR) | 0.33 | 0.16 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 70.33 | 7.59 |
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.